Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study.

@article{Haddad2003HerceptinIP,
  title={Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study.},
  author={Robert I. Haddad and Alexander Dimitrios Colevas and Jeffrey F Krane and Dennis L. Cooper and Bonnie S. Glisson and Philip C. Amrein and Linda Weeks and Rosemary Costello and Marshall Posner},
  journal={Oral oncology},
  year={2003},
  volume={39 7},
  pages={724-7}
}
Phase II study of Herceptin (Trastuzumab) in patients with advanced salivary gland tumors overexpressing Her2/neu. Patients with advanced, incurable salivary gland tumors and 2(+) or 3(+) Her2/neu expression in their tumors were enrolled in the study. After an initial dose of 4 mg/kg, patients received 2 mg/kg weekly. Patients were treated until they experienced progression of disease or unacceptable toxicity. The study was closed early when it has become clear that the majority of tumors… CONTINUE READING

From This Paper

Topics from this paper.
72 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 72 extracted citations

Similar Papers

Loading similar papers…